EC

Emilio Cosimo

Rouken Bio, Emilio Cosimo Consulting, University of Glasgow, Università degli Studi di Genova, TC Biopharm (United Kingdom)

ORCID iD 0000-0002-7294-222X
Follow

About

Emilio Cosimo recently joined RoukenBio, a Scottish CRO, as Scientific Director of Innovation. In this role, he leads the development of advanced platforms and services that help translate early-stage scientific discoveries into clinical solutions.

Emilio earned his PhD in Targeted Radiotherapy and Gene Therapy from the University of Glasgow, where his research focused on tumour-specific gene expression and radionuclide delivery for neuroblastoma.

Following his PhD, Emilio remained in academia, studying protein function in breast cancer and investigating novel therapies and mechanisms of drug resistance in chronic lymphocytic leukaemia. He later transitioned into industry, where he led the development of allogeneic “off-the-shelf” cell therapies and next-generation CAR-T platforms targeting solid tumours.

Emilio is passionate about bridging science and commercial strategy to deliver impactful therapies that improve patient outcomes.

Outside of work, Emilio is a passionate ultramarathon runner and a keen guitarist.

Employment

  • Rouken Bio Scientific Director
    2025 - Present
  • Emilio Cosimo Consulting Director
    2024 - 2025
  • TC Biopharm (United Kingdom) Director of Product Development
    2022 - 2024
  • TC Biopharm (United Kingdom) Manager
    2020 - 2022
  • Reprocell Europe Ltd Senior Scientist/Study Director
    2019 - 2020
  • TC Biopharm (United Kingdom) Senior Scientist
    2017 - 2019

Education

  • University of Glasgow PhD
    2002 - 2007
  • Università degli Studi di Genova Bsc/Msc
    1993 - 1998

Projects & Funding

Projects & funding information is unavailable.

Publications (44)

  • A Phase I Trial of Allogeneic γδ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia
    Clinical Lymphoma Myeloma and Leukemia 2023 DOI: 10.1016/j.clml.2023.02.003
    +Save
  • AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
    Clinical cancer research : an official journal of the American Association for Cancer Research 2018 DOI: 10.1158/1078-0432.ccr-18-2036
    +Save
  • The dual mTOR kinase inhibitor, AZD8055, synergises with ibrutinib to induce CLL apoptosis, and overcomes BCR- and stromal-mediated survival advantages conferred in the microenvironment
    British Journal of Haematology 2018
    +Save
  • Targeting chronic lymphocytic leukaemia (CLL) cellular migration with the dual mTor inhibitor AZD8055: an emerging therapeutic approach
    Leukemia & Lymphoma 2017
    +Save
  • Investigating the functional and molecular impact of BTK inhibition on mTOR kinase signalling in CLL cells
    Scottish Medical Journal 2016
    +Save
  • Preclinical development of a bispecific antibody that safely and effectively targets CD47 for the treatment of B cell cancers
    European Journal of Immunology 2016
    +Save
  • Synergy achieved when co-engaging CD47 and CD19 as targets in B cell malignancies
    European Journal of Cancer 2016
    +Save
  • Dual mTOR inhibition is an effective therapeutic approach for reducing tumour load in chronic lymphocytic leukaemia
    British Journal of Haematology 2015
    +Save
  • The ATP-Competitive mTOR Inhibitor AZD8055 Reduces Cell Proliferation and Tumour Load in Chronic Lymphocytic Leukaemia
    Blood 2015
    +Save
  • Subversion of Pkca and Pkcbii Upregulation Play an Essential Role in Chronic Lymphocytic Leukaemia Development, Inducing Constitutive B Cell Receptor-Mediated Signals
    Blood 2015
    +Save